Breast tumors interfere with endothelial TRAIL at the premetastatic niche to promote cancer cell seeding.
Journal
Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440
Informations de publication
Date de publication:
22 03 2023
22 03 2023
Historique:
entrez:
22
3
2023
pubmed:
23
3
2023
medline:
25
3
2023
Statut:
ppublish
Résumé
Endothelial cells (ECs) grant access of disseminated cancer cells to distant organs. However, the molecular players regulating the activation of quiescent ECs at the premetastatic niche (PMN) remain elusive. Here, we find that ECs at the PMN coexpress tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its cognate death receptor 5 (DR5). Unexpectedly, endothelial TRAIL interacts intracellularly with DR5 to prevent its signaling and preserve a quiescent vascular phenotype. In absence of endothelial TRAIL, DR5 activation induces EC death and nuclear factor κB/p38-dependent EC stickiness, compromising vascular integrity and promoting myeloid cell infiltration, breast cancer cell adhesion, and metastasis. Consistently, both down-regulation of endothelial TRAIL at the PMN by proangiogenic tumor-secreted factors and the presence of the endogenous TRAIL inhibitors decoy receptor 1 (DcR1) and DcR2 favor metastasis. This study discloses an intracrine mechanism whereby TRAIL blocks DR5 signaling in quiescent endothelia, acting as gatekeeper of the vascular barrier that is corrupted by the tumor during cancer cell dissemination.
Identifiants
pubmed: 36947620
doi: 10.1126/sciadv.add5028
pmc: PMC10032608
doi:
Substances chimiques
Ligands
0
Receptors, TNF-Related Apoptosis-Inducing Ligand
0
TNF-Related Apoptosis-Inducing Ligand
0
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
eadd5028Références
FEBS J. 2021 Oct;288(19):5530-5554
pubmed: 33215853
Mol Ther. 2013 Aug;21(8):1570-8
pubmed: 23799535
Cancer Cell. 2013 Feb 11;23(2):249-62
pubmed: 23410977
J Leukoc Biol. 2011 Nov;90(5):855-65
pubmed: 21562052
Physiol Rev. 2019 Jul 1;99(3):1467-1525
pubmed: 31140373
Dev Cell. 2020 Mar 23;52(6):714-730.e5
pubmed: 32109381
Signal Transduct Target Ther. 2020 Mar 12;5(1):28
pubmed: 32296047
FEBS Lett. 1999 Oct 22;460(1):129-33
pubmed: 10571074
Cancer Cell. 2013 Nov 11;24(5):673-85
pubmed: 24139859
Physiol Rev. 2020 Jan 1;100(1):1-102
pubmed: 31414610
Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3725-30
pubmed: 21321210
Oncogene. 2016 Mar 10;35(10):1261-70
pubmed: 26050621
Cancer Cell. 2009 Mar 3;15(3):167-70
pubmed: 19249675
Front Med (Lausanne). 2018 Jul 27;5:212
pubmed: 30101145
Atherosclerosis. 2016 Apr;247:87-96
pubmed: 26878368
Nature. 2020 Nov;587(7835):619-625
pubmed: 33208946
Front Immunol. 2019 May 22;10:1078
pubmed: 31231358
Cancer Cell. 2009 Mar 3;15(3):232-9
pubmed: 19249681
Oncotarget. 2016 Jul 5;7(27):41662-41676
pubmed: 27191500
Oncotarget. 2017 Nov 30;8(67):112132-112144
pubmed: 29340117
Cell. 2020 Feb 20;180(4):764-779.e20
pubmed: 32059779
Front Mol Biosci. 2021 Mar 10;8:628332
pubmed: 33791337
FEBS J. 2014 Mar;281(5):1505-1513
pubmed: 24438025
Science. 1997 Aug 8;277(5327):815-8
pubmed: 9242610
Oncotarget. 2017 May 29;8(33):55684-55714
pubmed: 28903453
Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):18324-9
pubmed: 22021440
J Biol Chem. 2007 Aug 10;282(32):23679-86
pubmed: 17553806
Nat Rev Cancer. 2016 Apr;16(4):201-18
pubmed: 27009393
EMBO Mol Med. 2021 Nov 8;13(11):e14495
pubmed: 34542930
J Control Release. 2018 Dec 10;291:106-115
pubmed: 30336167
Mol Cell. 2017 Feb 16;65(4):730-742.e5
pubmed: 28212753
Free Radic Biol Med. 2018 Oct;126:341-349
pubmed: 30165101
J Biol Chem. 2003 Feb 14;278(7):5444-54
pubmed: 12466268
Curr Protoc Immunol. 2001 May;Chapter 20:Unit 20.2
pubmed: 18432775
Vasc Biol. 2020 Jun 15;2(1):R73-R84
pubmed: 32923976
Mol Ther Nucleic Acids. 2019 Apr 15;15:26-35
pubmed: 30933724
Cancer Discov. 2021 Apr;11(4):933-959
pubmed: 33811125
Angew Chem Int Ed Engl. 2012 Aug 20;51(34):8529-33
pubmed: 22782619
Science. 2018 Feb 23;359(6378):935-939
pubmed: 29472486
J Clin Invest. 1999 Jul;104(2):155-62
pubmed: 10411544
Nat Commun. 2019 Feb 27;10(1):963
pubmed: 30814501
Science. 1997 Aug 8;277(5327):818-21
pubmed: 9242611
J Immunol. 2003 Aug 1;171(3):1526-33
pubmed: 12874246
Mol Cell. 2017 Feb 16;65(4):715-729.e5
pubmed: 28212752
Nat Med. 1999 Feb;5(2):157-63
pubmed: 9930862
Cancer Cell. 2012 Jul 10;22(1):80-90
pubmed: 22789540
J Immunol. 2002 Feb 1;168(3):1356-61
pubmed: 11801676
Mol Cell Biol. 2006 Oct;26(19):7046-55
pubmed: 16980609
Cell Death Differ. 2014 Sep;21(9):1350-64
pubmed: 24948009
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
J Immunol Res. 2015;2015:680749
pubmed: 25759846
Immunity. 2021 Dec 14;54(12):2877-2892.e7
pubmed: 34852217
Cancer Cell. 2015 Apr 13;27(4):561-73
pubmed: 25843002
J Clin Invest. 2014 Jun;124(6):2626-39
pubmed: 24789911
Nat Protoc. 2021 Jan;16(1):239-262
pubmed: 33247285
Cell Death Discov. 2020 Mar 17;6:14
pubmed: 32194994
Semin Cell Dev Biol. 2015 Mar;39:26-34
pubmed: 25655947
Cell Death Differ. 2013 Jul;20(7):858-68
pubmed: 23579241
Cancer Discov. 2022 Jan;12(1):31-46
pubmed: 35022204
Cell Metab. 2018 Dec 4;28(6):881-894.e13
pubmed: 30146488
Mol Cancer. 2010 Sep 17;9:250
pubmed: 20849618
J Clin Invest. 2008 Jan;118(1):100-10
pubmed: 18079967
Nat Rev Cancer. 2017 May 24;17(6):352-366
pubmed: 28536452
Blood. 2008 Mar 1;111(5):2647-56
pubmed: 17993608
Circulation. 2003 May 6;107(17):2250-6
pubmed: 12668516
Nat Rev Cancer. 2017 May;17(5):302-317
pubmed: 28303905
Nat Med. 2001 Jan;7(1):94-100
pubmed: 11135622
J Exp Med. 2001 Mar 19;193(6):661-70
pubmed: 11257133
Sci Data. 2018 Aug 21;5:180160
pubmed: 30129931